Serum Levels of Adipocyte Fatty Acid–Binding Protein Are Independently Associated With Left Ventricular Mass and Myocardial Performance Index in Obstructive Sleep Apnea Syndrome. (1st October 2012)

• Record Type: Journal Article
• Authors: Balci, Mustafa Mücahit; Arslan, Uğur; Firat, Hikmet; Kocaoğlu, İbrahim; Vural, Mustafa Gökhan; Balci, Kevser Gülcihan; Maden, Orhan; Gürbüz, Oğuz Alp; Ardiç, Sadık; Yeter, Ekrem
• Is Part Of: Journal of investigative medicine. Volume 60:Number 7(2012)
• Page Start: 1020
• Page End: 1026
• Publication Date: 2012-10-01
• Subjects: adipocyte fatty acid binding protein -- obstructive sleep apnea -- echocardiography; Clinical medicine -- Periodicals; Medicine -- Research -- Periodicals; Medicine; Research -- United States; Clinical medicine; Medicine -- Research; Periodicals; 616.075
• DOI: 10.2310/JIM.0b013e31826868f2
• Languages: English
• ISSNs: 1081-5589

Abstract

Abstract : Objective: To investigate the cross-sectional association between serum adipocyte fatty acid–binding protein (A-FABP) level and diagnosis or severity of obstructive sleep apnea syndrome (OSAS) and some echocardiographic indices related with cardiac dysfunction. Methods: In this study, plasma A-FABP and high-sensitivity C-reactive protein concentrations were measured, and echocardiography was performed in subjects without any cardiac or pulmonary disease who were referred for evaluation of OSAS. According to the apnea-hypopnea index (AHI), subjects were classified into 3 groups: control group (AHI <5; n = 33), mild to moderate OSAS (30 > AHI ≥ 5; n = 30), and severe OSAS (AHI ≥ 30; n = 31). Results: Levels of A-FABP were significantly different between the groups ( P < 0.001). After post hoc analyses, all 3 groups were also significantly different from each other. The levels of A-FABP were significantly higher in the patients with severe OSAS (36.4 ± 13.0 ng/mL) than in the control subjects (9.3 ± 4.6 ng/mL; P < 0.0001) or in patients with mild-moderate OSAS (24.5 ± 10.5 ng/mL; P < 0.001). Patients with myocardial performance index (MPI) greater than 0.47 had higher serum A-FABP levels than those with MPI of less than 0.47 (31.8 ± 13.2 ng/mL vs 10.9 ± 6.3 ng/mL; P = 0.001). Multivariable regression analyses revealed that increased serum A-FABP concentrations were independently associated with increased left ventricular mass index (β = 0.195; P = 0.033) and increased MPI (β = 0.165; P = 0.015). Conclusions: Increased A-FABP levels were found in the patients with OSAS, which were correlated significantly with left ventricular mass index and MPI. Further prospective studies are needed to clarify whether increased serum A-FABP level is a marker or a potential mechanism for left ventricular involvement in patients with OSAS.